Antigenic Peptide Fragments for Down Syndrome Amyloid Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease-like dementia in individuals with Down's syndrome are inadequate, as existing therapies show little efficacy and are not specifically targeted at the unique amyloid-related pathology in this population, leading to significant cognitive and memory impairments.
Innovation Solution
Development of antigenic peptide fragments derived from amyloid protein or amyloid-like proteins, particularly amyloid-beta, for use in preventing or alleviating memory and cognitive impairments by targeting specific brain regions such as the hippocampus, prefrontal cortex, and entorhinal cortex, administered to children and young to middle-aged individuals with Down's syndrome to prevent or reduce amyloid plaque formation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current Alzheimer's disease treatments (cholinesterase inhibitors or NMDA receptor antagonists) are used in individuals with Down's syndrome, then general Alzheimer's symptoms may be addressed, but efficacy is lacking and they do not specifically target amyloid-related pathology in Down's syndrome
Solution Approach 1:
The patent applies local quality by developing a vaccine specifically tailored to Down's syndrome pathology rather than using general Alzheimer's treatments. The antigenic peptide is selected to match the specific amyloid-beta sequence produced in Down's syndrome (derived from the triplicate APP gene on chromosome 21), making the treatment locally adapted to the unique biological characteristics of this population.
Solution Approach 2:
The patent segments the treatment approach by focusing specifically on amyloid-beta immunotherapy rather than using broad-spectrum Alzheimer's medications. The antigenic peptide is a specific fragment (e.g., Aβ1-15 or Aβ22-35) that targets the amyloid component of Down's syndrome pathology, separating this specific mechanism from general cholinergic or glutamatergic modulation.
2Reliability
If amyloid-modifying treatments are developed to specifically target Aβ in Down's syndrome, then cognitive and memory impairments may be improved, but there is a risk of inducing side effects such as meningoencephalitis or microhemorrhage
Solution Approach 1:
The patent applies parameter changes by carefully selecting and optimizing the antigenic peptide parameters (sequence, length, conformation) to achieve effective Aβ targeting while minimizing immunogenicity that could lead to adverse events. The peptide is designed to be immunogenic enough to produce protective antibodies but not so immunogenic as to trigger severe inflammatory responses.
Solution Approach 2:
The patent uses an intermediary approach by employing a specific antigenic peptide as a mediator between the immune system and amyloid-beta pathology. This peptide acts as a controlled interface that stimulates protective immunity against Aβ without directly exposing the brain to harmful inflammatory agents, thereby reducing the risk of meningoencephalitis or microhemorrhage.
3Force
If treatments are administered to young to middle-aged individuals with Down's syndrome (below age 65), then prevention of amyloid plaque formation may be achieved, but the safety profile must be maintained in a vulnerable population
Solution Approach 1:
The patent applies preliminary action by administering the vaccine to young to middle-aged individuals with Down's syndrome (below age 65) before significant amyloid plaque burden develops. This preventive approach aims to establish protective immunity early in the disease process, preventing plaque formation rather than treating established pathology, thereby reducing both efficacy requirements and safety risks.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antigenic peptide fragments effectively prevent or reduce amyloid plaque formation in the brain, leading to improved memory and cognitive functions without inducing side effects like meningoencephalitis or microhemorrhage, and can be administered to individuals below the age of 65, including children, to restore or enhance recognition memory, contextual associative memory, and associative learning.
Implementation Method 1
The Aβ oligomers are today considered as the most toxic Aβ species, which impairs most cognitive functions in DS people. The antibodies generated by the anti-Aβ vaccine will bind to fibrillar Aβ deposits to eventually solubilize or inhibit the growth of the pre-plaques.
Data Source
AI summary
The present invention provides means for treating, alleviating and preventing amyloid-related pathology in young to middle-aged subjects with Down's syndrome (DS). In particular, the present invention provides antigenic peptide fragments derived from amyloid protein or amyloid-like protein for use in the preventive treatment of amyloid-related pathology in young to middle-aged subjects with Down's syndrome.